Somatostatin receptors in Neuro2A neuroblastoma cells: Operational characteristics

被引:16
作者
Koenig, JA [1 ]
Edwardson, JM [1 ]
Humphrey, PPA [1 ]
机构
[1] UNIV CAMBRIDGE,DEPT PHARMACOL,CAMBRIDGE CB2 1QJ,ENGLAND
基金
英国惠康基金;
关键词
somatostatin receptors; Neuro2A cells; adenylyl cyclase inhibition; ligand binding; I-125]-BIM-23027;
D O I
10.1038/sj.bjp.0700858
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 We have used somatostatin (SRIF) receptor subtype-selective ligands to determine some of the operational characteristics of somatostatin receptors in Neuro2A mouse neuroblastoma cells. The potent SRIF(1)-receptor selective ligand, BIM-23027, was able to displace completely the specific binding of radioiodinated somatostatin, [I-125]-Tyr(11)-SRIF-14, with a pIC(50) of 10.3, suggesting that Neuro2A cells contain predominantly receptors of the SRIF(1) receptor group. The rank order of affinities for several somatostatin analogues tested in competition studies, together with the high affinity of BIM-23027, indicate that the majority of receptors in Neuro2A cells are of the sst(2) subtype. 2 The stable radioligand, [I-125]-BIM-23027, bound with high affinity (K-d = 13 pM, B-max= 0.2 pmol mg(-1) protein) to Neuro2A cell membranes, but its binding was only partially reversible at room temperature and below. Thus at 4 degrees C, only 36% of the bound ligand dissociated within 2 h. In contrast, 60% of the ligand dissociated at 15 degrees C and 89% of the ligand dissociated at 37 degrees C. 3 Equilibrium binding of [I-125]-BIM-23027 was partially (25%) inhibited by 10 mu M GTP, and by 120 mM NaCl (42% inhibition) but this inhibition was increased to 75% when sodium chloride and GTP were added together. This effect of GTP and sodium chloride was also seen in dissociation experiments. After incubation to equilibrium with [I-125]-BIM-23027, dissociation was initiated with excess unlabelled ligand in the presence of GTP (10 mu M) and sodium chloride (120 mM). Under these conditions 67% of the ligand dissociated at 4 degrees C, 81% at 15 degrees C and 93% at 37 degrees C. Binding was totally inhibited by pretreatment of cells with pertussis toxin. 4 Functionally, BIM-23027 inhibited forskolin-stimulated cyclic AMP accumulation in a concentration-dependent manner with an IC50 of 1.0 nM and a maximal inhibition of 37%. This effect was abolished by pretreatment of the cells with pertussis toxin. However, unlike in studies reported with the recombinant sst(2) receptor, no rise in intracellular calcium concentration was observed with SRIF-14. 5 We conclude that Neuro2A cells provide a stable neuronal cell line for the study of functionally coupled endogenous somatostatin receptors of the sst(2) type. In addition, we have found that activation of the receptor is associated with ligand-receptor internalisation.
引用
收藏
页码:45 / 51
页数:7
相关论文
共 37 条
[1]   PHOSPHOLIPASE-C ACTIVATION AND CA2+ MOBILIZATION BY CLONED HUMAN SOMATOSTATIN RECEPTOR SUBTYPES-1-5, IN TRANSFECTED COS-7 CELLS [J].
AKBAR, M ;
OKAJIMA, F ;
TOMURA, H ;
MAJID, MA ;
YAMADA, Y ;
SEINO, S ;
KONDO, Y .
FEBS LETTERS, 1994, 348 (02) :192-196
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]   INHIBITION OF CELL-PROLIFERATION BY THE SOMATOSTATIN ANALOG RC-160 IS MEDIATED BY SOMATOSTATIN RECEPTOR SUBTYPES SSTR2 AND SSTR5 THROUGH DIFFERENT MECHANISMS [J].
BUSCAIL, L ;
ESTEVE, JP ;
SAINTLAURENT, N ;
BERTRAND, V ;
REISINE, T ;
OCARROLL, AM ;
BELL, GI ;
SCHALLY, AV ;
VAYSSE, N ;
SUSINI, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) :1580-1584
[4]  
CASTRO SW, 1996, BRIT J PHARMACOL, V117, P63
[5]  
GARCIA PD, 1994, MOL PHARMACOL, V45, P402
[6]   THE SOMATOSTATIN RECEPTORS SSTR1 AND SSTR2 ARE COUPLED TO INHIBITION OF ADENYLYL-CYCLASE IN CHINESE-HAMSTER OVARY CELLS VIA PERTUSSIS-TOXIN-SENSITIVE PATHWAYS [J].
HERSHBERGER, RE ;
NEWMAN, BL ;
FLORIO, T ;
BUNZOW, J ;
CIVELLI, O ;
LI, XJ ;
FORTE, M ;
STORK, PJS .
ENDOCRINOLOGY, 1994, 134 (03) :1277-1285
[7]  
HOFLAND LJ, 1995, ENDOCRINOLOGY, V136, P36998
[8]  
Holloway S, 1996, NEUROPHARMACOLOGY, V35, P1109
[9]  
HOYER D, 1994, N-S ARCH PHARMACOL, V350, P441
[10]  
HOYER D, 1995, TRENDS PHARMACOL SCI, V16, P81